Switch theme
Sign up to access all valuation multiples
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
2016
131
LTM Revenue $4.1M
Last FY EBITDA -$138M
-$30.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prelude Therapeutics has a last 12-month revenue (LTM) of $4.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prelude Therapeutics achieved revenue of $7.0M and an EBITDA of -$138M.
Prelude Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prelude Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Profit | $4.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$138M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1971% | XXX | XXX | XXX |
| EBIT | -$140M | XXX | -$140M | XXX | XXX | XXX |
| EBIT Margin | -3409% | XXX | -1996% | XXX | XXX | XXX |
| Net Profit | -$130M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | -3174% | XXX | -1817% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Prelude Therapeutics's stock price is $1.
Prelude Therapeutics has current market cap of $50.2M, and EV of -$30.9M.
See Prelude Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$30.9M | $50.2M | XXX | XXX | XXX | XXX | $-1.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Prelude Therapeutics has market cap of $50.2M and EV of -$30.9M.
Prelude Therapeutics's trades at -4.4x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Prelude Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prelude Therapeutics has a P/E ratio of -0.4x.
See valuation multiples for Prelude Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50.2M | XXX | $50.2M | XXX | XXX | XXX |
| EV (current) | -$30.9M | XXX | -$30.9M | XXX | XXX | XXX |
| EV/Revenue | -7.5x | XXX | -4.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | -7.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrelude Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.1M for the same period.
Prelude Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prelude Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prelude Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1971% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1686% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2096% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prelude Therapeutics acquired XXX companies to date.
Last acquisition by Prelude Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Prelude Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prelude Therapeutics founded? | Prelude Therapeutics was founded in 2016. |
| Where is Prelude Therapeutics headquartered? | Prelude Therapeutics is headquartered in United States of America. |
| How many employees does Prelude Therapeutics have? | As of today, Prelude Therapeutics has 131 employees. |
| Who is the CEO of Prelude Therapeutics? | Prelude Therapeutics's CEO is Dr. Krishna Vaddi, PhD. |
| Is Prelude Therapeutics publicy listed? | Yes, Prelude Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Prelude Therapeutics? | Prelude Therapeutics trades under PRLD ticker. |
| When did Prelude Therapeutics go public? | Prelude Therapeutics went public in 2020. |
| Who are competitors of Prelude Therapeutics? | Similar companies to Prelude Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Prelude Therapeutics? | Prelude Therapeutics's current market cap is $50.2M |
| What is the current revenue of Prelude Therapeutics? | Prelude Therapeutics's last 12 months revenue is $4.1M. |
| What is the current EV/Revenue multiple of Prelude Therapeutics? | Current revenue multiple of Prelude Therapeutics is -7.5x. |
| Is Prelude Therapeutics profitable? | Yes, Prelude Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
